US regulatory status: approved.
pharma · Syphilis · Human Immunodeficiency Virus
MEDA Pharma GmbH
MEDA Pharma GmbH & Co. KG
MEDA Pharma GmbH drug portfolio — 28 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Bad Homburg, DE HQ
89 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Bad Homburg, DE
- Employees
- 89
- Programs
- 8
- Drugs
- 28
- Patents
- 0
MEDA Pharma GmbH pipeline
Portfolio lens on 28 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
MEDA Pharma GmbH drug portfolio — 28 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records.
-
baricitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records.
-
bictegravir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in MEDA Pharma GmbH's portfolio. Molecular target: Human immunodeficiency virus type 1 integrase.
- Target
- Human immunodeficiency virus type 1 integrase
- Mechanism
- Human immunodeficiency virus type 1 integrase inhibitor
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
dexamethasone phosphate
Systemic hormonal preparations (H02)Systemic hormonal preparations (H02) compound in MEDA Pharma GmbH's portfolio.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
doravirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator
-
empagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H2 receptor.
- Target
- Histamine H2 receptor
- Mechanism
- Histamine H2 receptor antagonist
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records.
-
lamivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Activin receptor type-1.
- Target
- Activin receptor type-1
- Mechanism
- Tyrosine-protein kinase receptor FLT3 inhibitor
-
palonosetron
Alimentary tract and metabolism (A04)Alimentary tract and metabolism (A04) compound in MEDA Pharma GmbH's portfolio. Mechanism: Serotonin 3a (5-HT3a) receptor antagonist.
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records.
-
plitidepsin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in MEDA Pharma GmbH's portfolio. Molecular target: Elongation factor 1-alpha 2.
- Target
- Elongation factor 1-alpha 2
- Mechanism
- Elongation factor 1-alpha 2 inhibitor
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records.
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
remdesivir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: RNA-directed RNA polymerase L.
- Target
- RNA-directed RNA polymerase L
- Mechanism
- RNA-directed RNA polymerase L inhibitor
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records.
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records.
-
Development asset linked to MEDA Pharma GmbH in public FDA and regional records.